164 related articles for article (PubMed ID: 37014660)
1. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial.
Joensuu H; Wardelmann E; Eriksson M; Reichardt A; Hall KS; Schütte J; Cameron S; Hohenberger P; Sihto H; Jost PJ; Lindner LH; Bauer S; Nilsson B; Kallio R; Pesonen T; Reichardt P
Clin Cancer Res; 2023 Sep; 29(17):3313-3319. PubMed ID: 37014660
[TBL] [Abstract][Full Text] [Related]
2. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
3. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
4. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
[TBL] [Abstract][Full Text] [Related]
5. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
9. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
10.
Joensuu H
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568695
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
12. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Ramadori G; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Nilsson B; Sihto H; Bono P; Kallio R; Junnila J; Alvegård T; Reichardt P
J Clin Oncol; 2016 Jan; 34(3):244-50. PubMed ID: 26527782
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
14. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
[TBL] [Abstract][Full Text] [Related]
15. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Corless CL; Ballman KV; Antonescu CR; Kolesnikova V; Maki RG; Pisters PW; Blackstein ME; Blanke CD; Demetri GD; Heinrich MC; von Mehren M; Patel S; McCarter MD; Owzar K; DeMatteo RP
J Clin Oncol; 2014 May; 32(15):1563-70. PubMed ID: 24638003
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Vincenzi B; Napolitano A; Fiocco M; Mir O; Rutkowski P; Blay JY; Reichardt P; Joensuu H; Fumagalli E; Gennatas S; Hindi N; Nannini M; Spalato Ceruso M; Italiano A; Grignani G; Brunello A; Gasperoni S; De Pas T; Badalamenti G; Pantaleo MA; van Houdt WJ; IJzerman NS; Steeghs N; Gelderblom H; Desar IME; Falkenhorst J; Silletta M; Sbaraglia M; Tonini G; Martin-Broto J; Hohenberger P; Le Cesne A; Jones RL; Dei Tos AP; Gronchi A; Bauer S; Casali PG
Clin Cancer Res; 2022 Apr; 28(8):1672-1679. PubMed ID: 34615721
[TBL] [Abstract][Full Text] [Related]
17. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
19. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
20. Deciding on the duration of adjuvant therapy in gastrointestinal stromal tumor.
Whooley P; Correa E; von Mehren M
Expert Rev Anticancer Ther; 2021 May; 21(5):547-556. PubMed ID: 33353442
[No Abstract] [Full Text] [Related]
[Next] [New Search]
